Objective: High-density lipoprotein (HDL) function rather than absolute level may be a more accurate indicator for cardiovascular disease (CVD). Novel methods can measure HDL function using patient samples. The objective of this study is to identify factors that may contribute to HDL dysfunction in chronic treated HIV-1 infection.
INTRODUCTION
Cardiovascular disease (CVD) is a major cause of morbidity and mortality among HIV-1-infected individuals on effective antiretroviral therapy (ART). 1, 2 However, the exact mechanisms of increased CVD among HIV-1-infected persons remain unclear. Higher levels of high-density lipoprotein cholesterol (HDL-C) are an important negative indicator of CVD events. 3 ,4 HDL function rather than absolute level (HDL-C) may be a more accurate indicator of CVD risk, 5, 6 and recent studies confirm that CVD is strongly inversely correlated with cholesterol efflux capacity. 7 While HDL performs activities that are CVD-protective, in the setting of inflammation HDL becomes functionally impaired, elevating CVD risk. 8 Inflammation affects HDL by decreasing anti-inflammatory antioxidant factor levels and activity, increasing associated pro-inflammatory proteins, lipid hydroperoxide content and redox activity (oxidized HDL, HDLox) (independently of HDL levels), reducing cholesterol efflux potential, and diminishing HDL's ability to inhibit low-density lipoprotein oxidation. 8 HIV-1-infected ART-treated individuals have a higher prevalence of dyslipidemia and low HDL-C. 9 HIV-1-infected individuals also have impaired lipoprotein metabolism 10 and HDLox 11, 12 that have been associated with CVD in some but not all studies. [12] [13] [14] We found that HDLox but not oxidized low-density lipoproteins was independently and consistently associated with several biomarkers of systemic inflammation and immune activation in both ART-naive viremic and ART-treated individuals. 15 In a prospective study of 234 HIV-infected ARTnaive participants without CVD who were randomized to receive tenofovir-emtricitabine plus atazanavir/ritonavir, darunavir/ritonavir, or raltegravir (RAL) and achieved plasma HIV-1 RNA ,50 copies/mL by week 24, and thereafter HDLox declined over 96 weeks of ART. 14 Thus, given the emerging role of impaired HDL function in chronic treated HIV-1 infection it is important to understand predictors of HDL dysfunction in chronic HIV-1 infection.
Because of the complexity of the HDL particles, measurement of HDL function has been difficult to study in humans. 16, 17 Cell-free assays may give more robust measurements of HDL function compared with cell-based assays 12, 18 such as cholesterol efflux assays 16 that have several limitations including lack of standardization and significant heterogeneity with regard to types of cells and type of readout reported. 18 There is limited data regarding how different measures of HDL function (such as cholesterol efflux, antioxidant function, lipoprotein particle size) correlate to each other. ApoA-I, the major protein component of HDL, plays a key role in the promotion of cholesterol efflux 19 and its function is critical to its antiatherogenic molecular processes. 20 Modification of apoA-I impairs its ability to exchange on and off HDL, a critical process in reverse cholesterol transport, that is also a measure of HDL remodeling. 21, 22 HDL-apoA-I exchange (HAE) is markedly reduced when atherosclerosis is present, or when the subject carries at least 1 risk factor of CVD. 21, 22 A previously described cell-free assay based on electron paramagnetic resonance (EPR) spectroscopy, measures HAE, which provides a measure of HDL dynamics and the ability of HDL to remodel and release apoA-I. 21, 22 As spin-labeled apoA-I associates with HDL, the EPR spectra's peak amplitude increases because of structural changes in apoA-I from a lipid-free to a lipid-bound conformation. 22, 23 The HAE response relative to the maximal detectable HAE response (%HAE) provides a measure of the relative exchangeability of endogenous apoA-I and the dynamic nature of HDL particles. 22, 23 Early studies suggest that lower %HAE is a CVD-relevant measure of HDL function. 22, 23 In vitro studies suggest that oxidative modification of apoA-I may impair HDL's ability to mediate cholesterol efflux by inhibiting the remodeling/exchange of apoA-I. 21, 24 However, it is unknown how HDLox relates to HDL remodeling in vivo. We have developed a novel cell-free fluorometric method that measures HDL associated lipid peroxidation (HDLox) that offers a reproducible and rapid means of determining HDL function. 12 In certain populations of HIV-infected ART-treated participants the readout from this assay correlates with measures of subclinical atherosclerosis such as carotid intima media thickness 12 and calcium artery score. 13 We hypothesized that in chronic HIV-1 infection, increased oxidative stress and impaired antioxidant HDL function (as measured by higher HDLox) are associated with lower %HAE, and this association is independent of other factors associated with impaired HDL function in HIV-uninfected persons (such as elevated body mass index; BMI). 16, 17 There is also limited data regarding predictors of abnormal HDL function in chronic HIV-1 infection including the role of specific classes of antiretrovirals. The objectives of the present analysis were to characterize and evaluate in HIV-1-infected persons anthropometric (such as BMI 17 ) , laboratory (such as albumin that binds to reactive oxygen species and HDL and may affect HDL function 8 ) parameters and comorbidities (such as smoking, 25 kidney disease, 26 presence of metabolic syndrome 8 ) that may have a role in abnormal HDL function (antioxidant, cholesterol efflux; evidence based on HIVuninfected individuals 8, 17, 25, 26 ) . Toward this aim, we used a cross-sectional sample of ART-treated, viremic HIV-1-infected individuals and HIV-1 uninfected healthy controls (matched by race). We also compared these changes by ART regimen and hypothesized that RAL use would be associated with improved HDL function compared to protease inhibitors (PIs) within the HIV group. This is in light of previous studies where more favorable effects on lipids 27 and more prominent anti-inflammatory effects 28 were observed in RAL groups compared with protease inhibitor groups. Finally, since previous data suggest non-nucleoside reverse-transcriptase inhibitors (NNRTIs) have beneficial effect on HDL-C and cholesterol transport, 29 we hypothesized that NNRTI use would be associated with improved HDL function compared with PIs.
METHODS

Study Design and Participants
The Center for Clinical AIDS Research and Education (CARE) HDL function study was a cross-sectional study developed to assess determinants of impaired HDL function among HIV-infected patients on stable ART with HIV-1 RNA ,200 copies/mL within 6 months of enrollment compared with viremic HIV-1 infected ($200 copies/mL) and uninfected individuals. The cohort-enrolled participants $18-year aged men from the University of California, Los Angeles (UCLA) CARE clinic in Los Angeles, California in a single study visit that included biological specimen collection for storage and medical record review. HIV-1 uninfected $18 years of age men with no known dyslipidemia, metabolic, and inflammatory comorbidities and no known risk factors for CVD (except for smoking) were additionally recruited in outpatient clinics (such as primary care and general infectious diseases clinics) within UCLA. All individuals enrolled in the study provided written informed consent, and the study was approved by the UCLA Institutional Review Board.
Data Collection
Sociodemographic characteristics, comorbidities, presence of kidney disease [defined as glomerular filtration rate (GFR) , 60 mL$min 21 $1.73 cm 22 ], presence of risk factors for CVD (defined as at least one of the following: metabolic syndrome defined by National Cholesterol Education Program criteria, 30 diabetes, dyslipidemia, use of lipid lowering medication, hypertension, family history of CVD, Framingham 10-year Coronary Heart Disease Risk Score $10% risk), albumin, lipid profile were abstracted from the medical records for all study participants. In addition, for HIV-1-infected participants data that were also abstracted included duration of HIV-1 infection and ART, current (within 6 months) and nadir CD4 + T lymphocyte counts, plasma HIV-1 RNA levels.
Biomarker and Laboratory Assessment Plasma Lipid Analysis
The lipid panel (total cholesterol, HDL-C, and triglycerides) was measured in fasted EDTA-plasma by standard validated clinical assays using a Beckman DXC, and lowdensity lipoprotein cholesterol was calculated by the Friedewald formula. Plasma apoA-I levels were determined by validated nephelometric method as previously described. 22, 23 Oxidized HDL HDLox was quantified using a previously validated fluorometric biochemical assay that measures HDL lipid peroxidation based on the oxidation of the fluorochrome Amplex Red. 12 To reduce experimental variability and adjust for HDL amount, we normalized the mean fluorescence readout from quadruplicates of each sample (HDL ox _sample) by the mean fluorescence readout from quadruplicates of a pooled plasma control (HDL ox _control) and by concurrent HDL cholesterol concentration level (HDL-C) using the following calculation: "normalized" oxidized HDL (nHDL ox ) = [HDL ox _sample · 40 (mg/dL)]/[HDL ox _control · HDLCsample (mg/dL)], where 40 mg/dL represents HDL-C of the pooled plasma control. 14, 15 This approach has been validated in clinical studies and has been shown to reduce experimental variability. [11] [12] [13] [14] [15] 31, 32 Higher levels of this adjusted measure of HDL function have been associated with worse health outcomes. 12, 13, 17, 33 Throughout the results HDL ox is presented as normalized (nHDL ox ) measure to reflect the adjustment for experimental variability and HDL-C.
HAE Assay
HAE assays were performed as previously described. 22, 23 Freshly thawed plasma was mixed 1∶4 with phosphatebuffered saline (20 mM phosphate, 150 mM NaCl, pH 7.4), and 24% wt/vol PEG 6000 (Sigma) was added to a final concentration of 4%. Samples were centrifuged at 13,000 rpm for 10 minutes in a tabletop centrifuge at 4°C to remove apoB-containing lipoproteins. The clarified plasma was then mixed with 3 mg/mL spin-labeled apoA-I in a 3:1 ratio and drawn into an EPR-compatible borosilicate capillary tube (VWR). EPR measurements were performed with a Bruker eScan EPR spectrometer outfitted with temperature controller (Noxygen). Samples were scanned first at 6°C, incubated for 15 minutes at 37°C, and scanned again at 37°C. The peak amplitude of the nitroxide signal from spin-labeled apoA-I in the sample (3462-3470 Gauss) was compared with the peak amplitude of a proprietary internal standard (3507-3515 Gauss) provided by Bruker. The internal standard is contained within the eScan spectrometer cavity and does not contact the sample. Because the y-axis of an EPR spectrum is measured in arbitrary units, measuring the sample against a fixed internal standard facilitates normalization of sample response. HAE activity was determined by subtracting the sample:internal standard ratio obtained at 6°C from the sample:internal standard ratio at 37°C. The baseline spectra of spin-labeled apoA-I in phosphate-buffered saline were subtracted from results. Maximum amplitude of spin-labeled apoA-I was determined from spin-labeled apoA-I in a fully lipid-bound conformation, and %HAE was determined by dividing the calculated HAE response by the HAE maximum response. All samples were read in triplicate and averaged. HAE was calculated as described. 22, 23 Interassay coefficient of variability was 5.3%.
Statistical Analyses
Baseline characteristics were compared using parametric (such as analysis of variance) and nonparametric methods as appropriate for the data being evaluated. Pearson's correlation was used to evaluate the association between HDLox and %HAE (both log transformed) among all participants. Multivariate linear regression was used to investigate the predictors of HDLox and %HAE. Covariates significant in the univariate analysis (P , 0.10) were also examined together in multivariate analysis. For each set of hypotheses in multivariate analysis, the false discovery rate (FDR) was controlled at alpha = 0.05 using the BenjaminiHochberg procedure. 34 Statistical hypothesis tests were 2-sided with a significance threshold of 0.05 for P values. Based on our previous published studies on nHDLox among HIV-1-infected participants, [12] [13] [14] [15] 31, 32 and using a 2-sided, 0.05-level, 2-sample t test with 2 comparisons, a sample size of 40 individuals per group (HIV-1 versus uninfected individuals), provides at least 80% power to detect differences of at least 0.6 in effect size for HDLox (expressed as normalized ratio to a pooled plasma control from healthy donors; no units) between groups. All statistical analyses were conducted using JMP Pro 12.01 (SAS Institute, Cary, NC).
RESULTS
Baseline Characteristics
Baseline characteristics of the 198 participants are shown in Table 1 . Briefly, the median age of HIV-1-infected participants with suppressed viremia on ART (n = 116) was 47.5, 67% of them were nonhispanic white, the median CD4 T-cell count was 535 cells/mm 3 , and the group overall had a low CVD risk; only 9% of participants had a 10-year risk of hard coronary heart disease .6%, 20% were current smokers; 10% had metabolic syndrome. All HIV-1-infected persons were men who have sex with men (MSM). The most common ART regimen was efavirenz/emtricitabine/ tenofovir disoproxil fumarate (EFV/TDF/FTC) (23.7%) followed by TDF/FTC/darunavir/ritonavir (DRV/r) (16.1%) and TDF/FTC/RAL (11.9%). Only 28% of the viremic patients were ART naive, and the rest had virus resistant to ART at the time of the visit. The median age of HIV-1-infected participants with viremia (n = 50) was 45 years, and this group overall had a significantly higher CVD risk, lower median CD4 T-cell count and higher incidence of coinfections compared with the ART-treated groups (P , 0.05). There were no differences in other HIV-1 related parameters between the ART-treated and the viremic group (P . 0.05). The HIV-1 uninfected participants (n = 32) were younger (median age of 35 years) compared with HIV-1 uninfected participants (P , 0.001). Participants were similar across ART groups with the TDF/FTC backbone, and they were representative of the full substudy population (Supplemental Digital Content, Table 1 , http://links.lww.com/QAI/B2).
Comparison of Lipids and Parameters Related to HDL Function Between Groups
We explored differences in parameters previously reported to be associated with impaired HDL functions between study groups. Viremic HIV-1-infected participants had lower albumin, higher prevalence of kidney disease and smoking (P , 0.001) and lower HDL (P , 0.05) compared with ARTtreated and uninfected participants (Table 1) . HIV-1-infected participants had overall abnormal lipid profile and lower apoA-I levels compared with uninfected persons, whereas the ART-treated groups had overall similar lipid profile compared with the viremic group (Table 1) (P . 0.05).
Comparison of HDL Function Measures Between Groups
Median HDLox of viremic subjects, and ART-treated HIV-1-infected subjects was 35% and 17% higher, respectively, compared with uninfected participants (P , 0.001). Viremic and ART-treated HIV-1-infected subjects had a lower %HAE compared with uninfected participants (P , 0.01). Viremic subjects also had a lower %HAE compared with all the ART-treated groups (P , 0.01) ( Table 1) (Fig. 1) . Overall, HIV-1-infected persons had higher HDLox and lower %HAE compared with uninfected participants.
Correlates of HDL Remodeling in Chronic HIV-1 Infection Versus Uninfected Participants
To address our limited understanding of abnormal HDL function in chronic HIV-1 infection, we determined correlates of HDL remodeling (%HAE assay among HIV-1 groups). Among HIV-1-infected participants, there was a positive association between age, fasting lipids (total cholesterol, triglycerides), apoA-I, albumin, and %HAE (P , 0.05). By contrast, there was an inverse relationship between %HAE and BMI, HDLox, smoking, kidney disease (P , 0.05). The most notable positive associations were between %HAE and albumin and apoA-I (Table 2) , whereas lower %HAE was associated with higher HDLox. Regarding HIV-1-related parameters, only duration of HIV-1 infection and presence of viremia had a positive association with %HAE (Supplemental Digital Content, Table 2 , http://links.lww.com/QAI/B2). All associations between HDLox, apoA-I, and %HAE were attenuated but remained statistically significant (P , 0.05) after adjusting for FDR and covariates (age, race, BMI, lipids, apoA-I levels, presence of risks factors for CVD, kidney injury, albumin, viremia, current CD4 T-cell count, duration of HIV infection) (Table 3) . However, in HIV-1-uninfected participants only albumin demonstrated a moderate positive association with % HAE (Table 2) , even after adjusting for FDR and covariates (age, race, BMI, lipids, apoA-I). These results suggest that apoA-I in HIV-1 infected and albumin in uninfected participants, were the strongest positive correlates of HDL remodeling.
Correlates of Impaired Antioxidant Function in Chronic HIV-1 Infection Versus Uninfected Participants
We also explored correlates of the above parameters with another measure of HDL dysfunction, impaired antioxidant activity (HDLox). As expected in both HIV-1 infected and uninfected participants, higher BMI, smoking, kidney disease, and lower albumin were associated with higher HDLox (Table 4 ). Among HIV-1 infected but not in HIV-uninfected participants, white race, higher lipids (total cholesterol, triglycerides), lower apoA-I, presence of metabolic syndrome, and risk factors for CVD were associated with higher HDLox. The most notable positive associations were between HDLox and BMI (Table 4) , whereas HDLox was most strongly negatively associated with albumin and apoA-I. Regarding HIV-1-related parameters, only shorter duration of HIV-1 infection, lower CD4 T-cell count and higher viral load were associated with higher HDLox (Supplemental Digital Content, Table 2 , http://links. lww.com/QAI/B2). All associations were attenuated for BMI, apoA-I, smoking, albumin after adjusting for FDR and covariates (age, race, BMI, lipids, apoA-I, presence of risks factors for CVD, kidney injury, albumin, viremia, current CD4 T-cell count, duration of HIV infection) but remained statistically significant (Table 5 ). However, in HIV-1 uninfected participants none of the observed associations between HDLox and parameters remained significant (Table 5) , after adjusting for FDR and covariates (age, race, BMI, lipids, kidney injury, smoking, apoA-I). Overall, our data suggest that smoking, BMI, apoA-I, and albumin were among the most notable correlates of HDL dysfunction (using 2 different measures of HDL function).
Associations of HDL Function With ART
We then explored the association of different ART classes with HDL function. Overall, there was no ART classspecific (NRTI, versus NRRTIs, versus PIs, versus RAL) association between %HAE or HDLox (Supplemental Digital Content, Tables 1-3 , http://links.lww.com/QAI/B2). HIV-1-infected participants on ART with the same NRTI backbone (TDF/FTC) who received NNRTIs, PIs, or RAL had similar %HAE and HDLox levels (Supplemental Digital Content, Table 1 , http://links.lww.com/QAI/B2). NNRTI use was associated with lower HDLox in univariate analysis (Supplemental Digital Content, Table 3 , http://links.lww.com/ QAI/B2) but not in multivariate analysis after adjustment for covariates that may affect HDL function ( Table 5 ).
Correlations of Measures of HDL Function Among Groups
We determined whether HDLox correlates with HDL remodeling in vivo in chronic HIV-1 infection. Using Pearson correlation ( Fig. 2 ) and univariate analysis (Table 2) , there was a significant inverse relationship between HDLox and %HAE among all HIV-1-infected participants (r = 0.50, P , 0.001). This association was similar between the viremic (r = 20.42, P = 0.003) and the aviremic (r = 20.41, P , 0.001) HIV-1-infected participants (Fig. 2) but was not present in the uninfected individuals (r = 20.115, P = 0.42). HDLox correlated with %HAE (Table 2) in HIV-1-infected groups after adjustment for other clinical factors (Table 3) . 
Bold and italics indicate significance. Nominal P values presented. Those with FDR , 0.05 are italicized. *The covariates considered for HIV subjects were age, race (nonwhite versus white), BMI, fasting lipid measurements (total cholesterol, HDL-C), apoA-I levels, presence of risks factors for CVD (except for smoking), smoking, kidney injury, albumin, HIV status, viremia (yes/no), current CD4 T-cell count, duration of HIV infection. Additional model based on the above covariates plus HDLox (n = 149), gave similar estimates (not shown).
†The covariates considered for HIV-uninfected subjects were age, race (nonwhite versus white), BMI, apoA-I levels, albumin. Parsimonious multivariate models with fewer variables (age, BMI, TC, viremia, CD4 T-cell count) gave similar results (consistent correlates of primary outcome).
‡Except for smoking.
DISCUSSION
In this cross-sectional study of HIV-1-infected men with low overall CVD risk and healthy men with no known CVD risk, we found that chronic HIV-1 infection, despite effective ART, as well as viremia, were associated with impaired HDL function, as determined by 2 independent measures. Overall, HIV-1-infected persons had higher HDLox and lower %HAE compared with uninfected participants. The viremic group had approximately 18% mean relative impairment in antioxidant function and 9% relative mean impairment in HDL dynamics (%HAE) compared with HIV-1-infected participants on effective ART. After correcting for covariates that may affect HDL function, it was determined that the most notable correlates of impaired HDL function were BMI, apoA-I (inversely), and albumin (inversely). There were no consistent differences in both measures of HDL function between the different ART treatment groups. In HIV-1 uninfected persons, only albumin demonstrated a moderate positive association with %HAE, whereas none of the other significant correlates of abnormal HDL function in HIV-1-infected persons were found to correlate with HDLox and %HAE. The relatively small sample size and the low CVD risk 
Bold and italics indicate significance. Nominal P values presented. Those with FDR # 0.05 are italicized. *The covariates considered for HIV subjects were age, race (nonwhite versus white), BMI, fasting lipid measurements (total cholesterol), apoA-I, presence of risks factors for CVD, smoking, kidney injury, albumin, viremia (yes/no), current CD4 T-cell count. Additional models based on the above covariates plus NNRTI use (n = 131) and or %HAE (n = 149), gave similar estimates (not shown).
†The covariates considered for HIV-uninfected subjects were age, race (nonwhite versus white), BMI, fasting lipid measurements (total cholesterol) and albumin. Parsimonious multivariate models with fewer variables (age, BMI, TC, viremia, CD4 T-cell count) gave similar results (consistent correlates of primary outcome).
profile of the HIV-1 uninfected group who had normal lipid values may explain these observations and why we did not find an association between HDLox and %HAE. Considering that oxidative modification of HDL (higher HDLox) has been demonstrated in vitro to impair HDL-mediated cholesterol efflux and inhibit HDL remodeling (low %HAE), 21, 24 it is not surprising that higher HDLox is correlated with lower HDL remodeling in vivo in chronic HIV-1 infection. Overall, our data using novel measures of HDL function confirm previous evidence that HIV-1 infection is associated with impaired HDL function despite effective ART. 12, 32, [35] [36] [37] HDL oxidation may impair HDL function and HDL dynamics in HIV-1 infection and may have a central role in HIV pathogenesis that both result from and contribute to systemic inflammation of HIV infection. We addressed the limited understanding of the influence of chronic HIV-1 infection on HDL function by exploring the associations of independent measures of HDL function with covariates that may affect HDL function in uninfected persons. 8, 17, 25, 26 We found that in HIV-1-infected participants, lower apoA-I was independently associated with impaired HDL dynamics (lower %HAE) and that higher BMI, lower apoA-I, current smoking, lower albumin were independently associated with impaired HDL antioxidant function (higher HDLox). However, in HIV-1-uninfected participants, only albumin demonstrated a moderate positive association with %HAE (but not for HDLox), after adjusting for covariates. ApoA-I is the major protein in HDL and is known to have a major role in HDL function. 6 Albumin binds to HDL, has antioxidant activity, 38 and has previously been shown to affect HDL function. 8 Albumin represents a very abundant and important circulating antioxidant that attenuates oxidative damage. 38 Reactive oxygen species directly contribute to lipid peroxidation and can cause modifications in proteins (including apoA-I). Thus, it is not surprising that in our study lower albumin was independently associated with higher HDLox. These results parallel our results from a previous smallmatched cohort study of HIV-1-infected participants with low CVD risk profiles where HDLox was independently associated with anthropometric parameters of obesity. 31 Obesity and dietary fat can modulate ABCA1-dependent efflux, HDL-mediated activation of endothelial nitric oxide synthase, and HDL function. 39, 40 Smoking is known to affect oxidation of lipoproteins and lipoprotein metabolism, and it promotes atherogenesis. 41 We found that compared with uninfected controls, HIV-1-infected men on successful ART and low CVD risk had impaired HDL dynamics and antioxidant function. Initiation of ART among HIV-infected patients incompletely reduces markers of systemic inflammation. 42 HIV-1-infected individuals receiving ART may also have higher oxidative stress compared with HIV-1-infected ART-naive or healthy subjects because of higher production of free radical species, mitochondrial dysfunction, and alterations in antioxidant systems. 43 Herein, we showed that HDLox is associated with HDL remodeling in vivo in chronic HIV-1 infection. Previous studies demonstrate that HDL remodeling may be a CVDrelevant measure of HDL function and is associated with cholesterol efflux, one of the main HDL functions. 22, 23 In vitro studies indicate that oxidative modification of HDL may impair the cholesterol efflux and inhibit HDL remodeling/ exchange of apoA-I. 21, 24 Thus, HDL oxidation may impair HDL function and may have a central role in HIV pathogenesis. We previously showed that HDLox in HIV-1-infected subjects on long-term ART and without clinical CVD are (1) associated with in vivo progression of CVD, 12 (2) may stimulate endothelial cells to induce M/M chemotaxis, a measure of HDL function, 11 (3) correlated positively with noncalcified coronary atherosclerotic plaque, and 13 (4) independently correlated with several markers of systemic inflammation and immune activation in chronic HIV-1 infection. 15 Further studies are needed to characterize HDL dynamics, HDLox, different measures of HDL function including cholesterol efflux, and mechanisms of HDL dysfunction in HIV-1-infected persons on successful ART.
There are limited data regarding the effect of ART on oxidized lipoproteins, lipoprotein particle number and size and HDL function. 44 Contrary to our original hypothesis, RAL did not seem to have more favorable effects on HDLox and %HAE than protease inhibitor treatment. This is consistent with data from our recent prospective study where RAL initiation in ART-naive participants was not associated with favorable effects on HDLox. 14 We found in unadjusted analysis that NNRTI use was associated with reduced HDLox (but not %HAE), consistent with previous data that suggest NNRTI use has beneficial effect on HDL-C and cholesterol transport. 29 However, this relationship did not remain significant in the adjusted analysis. Further studies are needed to confirm the complex effects of ART on measures of HDL function.
The strengths of our study are the careful covariate phenotyping of our study population including novel measures of HDL function. However, there are limitations. Our study is cross-sectional, and therefore causality cannot be assessed and potential confounders such as lifestyle changes (especially in viremic patients) may not have been fully accounted for. The small size of our study limits our ability to detect clinically meaningful associations of ART with measures of HDL function and correlates of HDL function in HIV-1 uninfected participants. Further limitations are also recognized in the context of biochemical assays of HDL function. 11, 12 These limitations may compromise the ability to detect differences in measures of HDL function in a population with an overall low CVD risk. The current research focused on cell-free assays, and the cell-based cholesterol efflux assay was not performed. Finally, an important limitation of our study was the inclusion of men only. We recruited only men to avoid confounding from sex differences in lipid metabolism in this pilot study. 45 In conclusion, we determined parameters associated with abnormal HDL function using 2 independent measures of HDL functionality. HIV-1-infected men (even the ones on effective ART with low CVD risk) had impaired antioxidant function and HDL dynamics compared with HIV-1 uninfected men. Higher BMI, lower apoA-I, and lower albumin were among the most notable correlates of impaired HDL function among HIV-1-infected participants. There were no notable differences in HDL function among ART treatment groups. We found that HDLox is associated with HDL remodeling in vivo in chronic HIV-1 infection. Thus, larger prospective studies with longer-term treatments are needed to further study and understand the role of HDL function in HIV-1 pathogenesis.
